spacer
home > ebr > autumn 2017 > risk ratio
PUBLICATIONS
European Biopharmaceutical Review

Risk Ratio

On 30 August 2017, the US FDA formally approved the application for Kymriah, a cancer immunotherapy utilising modified human T-cells that express chimeric antigen receptors (CAR-T). This momentous event follows a decade of intense work to commercialise a therapy that was first demonstrated in 2011 in a handful of terminal paediatric leukaemia patients. At this moment, many CAR variants are in development, alongside a biotechnology business frenzy.

Pre-genomic immunotherapy consisted of human immunoglobulin injections to boost immunity during disease outbreaks. Clearly, this was a blunt instrument. Half a century later, a group at the University of Pennsylvania described remission in paediatric patients with refractory chronic lymphocytic leukaemia using genetically modified immune cells. Furthermore, at the beginning of September 2017, the first ever approval of CAR-T therapy was granted by the FDA for cases of acute lymphoblastic leukaemia in children and young adults. This inverts the usual regulatory paradigm by approving paediatric indications first.

In their Harvard Business Review paper ‘How to Spot a Technological Winner’, Graham and White discuss the factors that influence the success of a transformative innovation. The present intensity of the commercial race in cancer immunotherapy and gene-editing reflects a belief within the biopharmaceutical community that the trade-off of business drivers and technical hurdles is favourable. In just a few years, the number of groups working in this field has expanded from just a handful to over 200.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Emile Bellott is a member of the EBR Industry Advisory Board and an industry consultant with experience in drug discovery, development and pharmaceutical outsourcing.
spacer
Emile Bellott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Zenith Technologies Wins ‘Supplier of the Year’ at Pharma Industry Awards 2018

Zenith Technologies, a world leader in delivering manufacturing software to the life sciences industry, has been named ‘Pharma Supplier of the Year’ at the prestigious 2018 Pharma Industry Awards.
More info >>

White Papers

Data Technology as a Catalyst for Growth in the Life Sciences

AIGENPULSE

The life sciences industry is changing at a rapid pace. The need to develop the next blockbuster is pushing current technologies and methodologies to the limit. Scientific advancement over the last decades was embossed with giant leaps in knowledge, however, the new reality is that smaller incremental gains need to be carved out with ever increasing investments. In order to survive, progress and prosper in this new reality, a holistic approach to getting the most of research data is crucial. In fact, it will likely be the difference of being in existence in 5-10 years or not. For those bold enough to step into an area they are unfamiliar with, huge rewards are waiting.
More info >>

 
Industry Events

CPhI & P-MEC India 2018

12-14 December 2018, India Expo Mart, New Delhi, India

CPhI & P-MEC India (December 12-14, 2018) – organised by UBM (part of Informa PLC) – announces that the 12th edition of Asia’s largest Pharma exhibition is moving to the India Expo Mart, New Delhi. The new venue will see the exhibition now hosted in a single venue, bringing it closer to the Indian regulatory and legislative capital. New Delhi is also the country’s main international transport hub and will encourage an increased international attendance. In total, more than 50,000 people from 122 countries are expected, along with nearly 1,500 exhibitors.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement